Order of the President of the General Court of 22 June 2026.#Biohaven Bioscience Ireland Ltd and Biohaven Therapeutics Ltd v European Medicines Agency.#Interim relief – Medicinal products for human use – Regulation (EC) No 726/2004 – Withdrawal of the application for marketing authorisation for Dazluma – Publication of the assessment report – Application for suspension of operation – Prima facie case – Urgency – Weighing up of interests.#Case T-844/25 R.

Records

Official record CELEX 62025TO0844 from European Union at Court of Justice of the European Union. Dated 22 June 2026. Status: decided.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

2 official files

• Order of the President of the General Court of 22 June 2026.#Biohaven Bioscience Ireland Ltd and Biohaven Therapeutics Ltd v European Medicines Agency.#Interim relief – Medicinal products for human use – Regulation (EC) No 726/2004 – Withdrawal of the application for marketing authorisation for Dazluma – Publication of the assessment report – Application for suspension of operation – Prima facie case – Urgency – Weighing up of interests.#Case T-844/25 R.

  judgment · EN · 22 June 2026

  ViewDownloadOpen at official source

• Ordonnance du président du Tribunal du 22 juin 2026.#Biohaven Bioscience Ireland Ltd et Biohaven Therapeutics Ltd contre Agence européenne des médicaments.#Référé – Médicaments à usage humain – Règlement (CE) no 726/2004 – Retrait de la demande d’autorisation de mise sur le marché du Dazluma – Publication du rapport d’évaluation – Demande de sursis à exécution – Fumus boni juris – Urgence – Mise en balance des intérêts.#Affaire T-844/25 R.

  judgment · FR · 22 June 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.